A phase 1, first-in-human study of regorafenib plus temozolomide with or without radiotherapy in patients with newly diagnosed MGMT methylated, IDHwt glioblastoma: The REGOMA-2 trial.

Authors: Marta Padovan, Matteo Simonelli, Amedeo De Nicolò, Paola Del Bianco, Giulia Cerretti, Mario Caccese, Pasquale Persico, Giorgia Menegatti, Alberto Bosio, Angelo Dipasquale, Marta Maccari, Agnese Losurdo, Marina Coppola, Marco Krengli, Sara Lonardi, Antonio D'Avolio, Gian Luca De Salvo, Giuseppe Lombardi

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.2068

Source: Full article

---

Abstract

2068